Morphic Holding Inc (MORF)

$56.59

+0.07

(+0.12%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $56.46
    $56.59
    $56.59
    downward going graph

    0.23%

    Downside

    Day's Volatility :0.23%

    Upside

    0.0%

    downward going graph
  • $19.35
    $62.08
    $56.59
    downward going graph

    65.81%

    Downside

    52 Weeks Volatility :68.83%

    Upside

    8.84%

    downward going graph

Returns

PeriodMorphic Holding IncSector (Health Care)Index (Russel 2000)
3 Months
96.83%
5.3%
0.0%
6 Months
103.27%
6.3%
0.0%
1 Year
2.02%
9.2%
0.0%
3 Years
-6.14%
13.1%
-19.9%

Highlights

Market Capitalization
2.8B
Book Value
$13.25
Earnings Per Share (EPS)
-3.6
Wall Street Target Price
52.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.46%
Return On Equity TTM
-29.58%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-31.3M
EBITDA
-192.0M
Diluted Eps TTM
-3.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.95
EPS Estimate Next Year
-4.24
EPS Estimate Current Quarter
-0.93
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Morphic Holding Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 6.79%

Current $56.59
Target $52.75

Technicals Summary

Sell

Neutral

Buy

Morphic Holding Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Morphic Holding Inc
Morphic Holding Inc
80.28%
103.27%
2.02%
-6.14%
176.45%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Morphic Holding Inc
Morphic Holding Inc
NA
NA
NA
-3.95
-0.3
-0.21
NA
13.25
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Morphic Holding Inc
Morphic Holding Inc
Buy
$2.8B
176.45%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Morphic Holding Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 60.23M → -60.23M (in $), with an average decrease of 200.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -36.21M → -45.29M (in $), with an average decrease of 11.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 61.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 199.6%

Institutional Holdings

  • FMR Inc

    14.98%
  • Point72 Asset Management, L.P.

    9.36%
  • Wellington Management Company LLP

    8.03%
  • BlackRock Inc

    6.55%
  • State Street Corporation

    5.32%
  • T. Rowe Price Associates, Inc.

    5.04%

Corporate Announcements

  • Morphic Holding Inc Earnings

    Morphic Holding Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Organization
Morphic Holding Inc
Employees
124
CEO
Dr. Bruce N. Rogers Ph.D.
Industry
Health Technology

FAQs